

Image

Docket Number: 037003-0275470

PATENT APPLICATION

Client Reference: 1997-30-0565CP1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re The Application of REFF et al.

Group Art Unit: 1644

Application No.: 09/019,441

Examiner: P. Huynh

Filed: February 5, 1998

Confirmation No.: 2038

For: GAMMA-1 AND GAMMA-3 ANTI-HUMAN CD23 MONOCLONAL ANTIBODIES
AND USE THEREOF AS THERAPEUTICS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the listed references be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue there from.

Pursuant to 37 C.F.R. §1.97(b)(4), this Supplemental Information Disclosure Statement is being filed before the mailing of a first office action on the merits after the filing of a request for continued examination under 37 C.F.R. § 1.114.

It is believed that no fee is required for this submission. Please credit or debit Deposit Account 033975 as needed to ensure consideration of the disclosed information.

Respectfully Submitted,

Thomas A. Cawley, Jr., Ph.D.
Registration Number 40,944
Customer Number: 00909

Date: January 5, 2004
PILLSBURY WINTHROP LLP
Telephone: (703) 905-2000
Facsimile: (703) 905-2500
P.O. Box 10500
McLean, VA 22102
TAC/CR:ntb

FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office

Atty.
Dkt. No.

M#

Client Ref.

037003-0275470

1997-30-0565CP1

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Applicant: Mitchell E. REFF et al.

Appln. No.: 09/019,441

Filing Date: February 5, 1998

Examiner: P. Huynh

Group Art Unit: 1644

Date: January 5, 2004

Page

1

of

1

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR 6,001,358	12/1999	Black et al.	424	154.1	
	BR 6,136,310	10/2000	Hanna et al.	424	154.1	
	CR					

FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
					Enclosed	No	Enclose	No
	DR							
	ER							
	FR							
	GR							
	HR							

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

IR	Boulet et al., "Inhibitory Effects of an Anti-IgE Antibody E25 on Allergen-induced Early Asthmatic Response," <i>Am J Respir Crit Care Med</i> , (1997) 155:1835-44.
JR	Casale et al., "Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis," <i>J Allergy Clin Immunol</i> , (1997), 100:110-120.
KR	Coyle et al., "Central Role of Immunoglobulin (Ig) E in the Induction of Lung Eosinophil Infiltration and T Helper 2 Cell Cytokine Production: Inhibition by a Non-anaphylactogenic Anti-IgE Antibody," <i>J Exp Med</i> , (1996), 183:1303-1310.
LR	Fahy et al., "The Effect of an Anti-IgE Monoclonal Antibody on the Early-and Late-Phase Responses to Allergen Inhalation in Asthmatic Subjects," <i>Am J Respir Crit Care Med</i> , (1997), 155:1828-34.
MR	Ohashi et al., "Immunotherapy Affects the Seasonal Increase in Specific IgE and Interleukin-4 in Serum of Patients with Seasonal Allergic Rhinitis," <i>Scan J Immunol</i> , (1997), 46(1):67-77.
NR	Ohashi et al., "Serum levels of specific IgE, soluble interleukin-2 receptor, and soluble intercellular adhesion molecule-1 in seasonal allergic rhinitis," <i>Annals of Allergy, Asthma, and Immunol</i> , (1997), 79:213-220.
OR	Ohashi et al., "Ten-Year Follow-Up Study of Allergen-Specific Immunoglobulin E and Immunoglobulin G4, Soluble Interleukin-2 Receptor, Interleukin-4, Soluble Intercellular Adhesion Molecule-1 and Soluble Vascular Cell Adhesion Molecule-1 in Serum of Patients on Immunotherapy for Perennial Allergic Rhinitis," <i>Scand J Immunol</i> , (1998), 47:167-178.
PR	Peebles et al., "Ragweed-specific antibodies in bronchoalveolar lavage fluids and serum before and after segmental lung challenge: IgE and IgA associated with eosinophil degranulation," <i>J Allergy Clin Immunol</i> , (1998), 101:265-273.
QR	Pullerits et al., "An intranasal glucocorticoid inhibits the increase of specific IgE initiated during birch pollen season," <i>J Allergy Clin Immunol</i> , (1997), 100:601-605.
RR	Ward E.S. and Ghetie V., "The effector functions of immunoglobulins: implications for therapy," 1995, <i>Therapeutic Immunology</i> , 2:77-94.

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.